Fuji Pharma Co.,Ltd.
4554・Prime Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 9 directors (including 5 outside directors, 4 independent officers), and there are 3 corporate auditors (including 2 outside corporate auditors). Directors' term of office is one year. The company ensures that outside directors constitute a majority and has established voluntary Nomination and Compensation Committees (with a chairperson and a majority of members being independent outside directors). The Board of Directors met 13 times during the fiscal year under review.
Risk Management
The Risk Management Committee conducts risk assessments based on the
Shareholder Returns
Basic policy is to pay dividends twice a year, continuing a progressive dividend policy. The interim dividend for FY2026 (ending September 2026) is ¥23 (an increase from ¥20 in the prior-year interim), with a year-end forecast of ¥26 and a full-year forecast of ¥49 (an increase from ¥45.5 in the prior fiscal year). Share buybacks can be implemented flexibly based on Board of Directors resolutions.
Dividend Policy
Basic policy is to pay stable and continuous dividends, maintaining a progressive dividend policy under which dividends are not reduced. Dividends are paid twice a year: an interim dividend (record date March 31) and a year-end dividend. For FY2026 (ending September 2026), the interim dividend is ¥23, the year-end forecast is ¥26, and the full-year forecast is ¥49. The policy is to maintain a dividend payout ratio of 30% or more, excluding special factors.
ESG
The company has established a Sustainability Committee (meeting four times per year), chaired by the Representative Director and President, along with a dedicated department, to promote sustainability initiatives company-wide. In addressing climate change, the company conducts scenario analysis based on the TCFD recommendations, targeting the conversion of 50% of electricity usage at the Toyama Plant to renewable energy by 2030, with a goal of carbon neutrality by 2050. In terms of human capital, the company aims to raise the ratio of female managers from the current 20%, and has enhanced welfare benefits for women, including special leave for infertility treatment and expanded gynecological checkups. The turnover rate for FY2025 (ending September 2025) was 3.2% (improved from 3.6% in the previous fiscal year). In the final year of the medium-term management plan (FY2029, ending September 2029), the company targets an employee engagement positive response rate of 70% or higher and a turnover rate of 3% or lower.
Last updated: December 18, 2025